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Imprinted gene clusters are regulated by long noncoding RNAs (lncRNAs), CCCTC binding factor (CTCF)-mediated boundaries, and
DNA methylation. DIRAS3 (also known as ARH1 or NOEY1) is an imprinted gene encoding a protein belonging to the RAS superfamily
of GTPases and is located within an intron of a lncRNA called GNG12-AS1. In this study, we investigated whether GNG12-AS1 is
imprinted and coregulated with DIRAS3. We report that GNG12-AS1 is coexpressed with DIRAS3 in several tissues and coordinately
downregulated with DIRAS3 in breast cancers. GNG12-AS1 has several splice variants, all of which initiate from a single transcription
start site. In placenta tissue and normal cell lines, GNG12-AS1 is biallelically expressed but some isoforms are allele-specifically spliced.
Cohesin plays a role in allele-specific splicing of GNG12-AS1. In breast cancer cell lines with loss of DIRAS3 imprinting, DIRAS3 and
GNG12-AS1 are silenced in cis and the remaining GNG12-AS1 transcripts are predominantly monoallelic. The GNG12-AS1 locus, which
includesDIRAS3, provides an example of imprinted cotranscriptional splicing and a potential model system for studying the long-range
effects of CTCF-cohesin binding on splicing and transcriptional interference.Introduction
DIRAS family, GTP-binding RAS-like protein 3 (DIRAS3
[MIM 605193]) is imprinted, widely expressed in many
adult tissues, and downregulated in several cancers,
including breast and ovarian cancers.1–3 As a tumor sup-
pressor, DIRAS3 has been reported to have a role in
cell migration,4–7 proliferation,8,9 apoptosis,10,11 and auto-
phagy.10,12
At the DIRAS3 locus, a long noncoding RNA (lncRNA)
named LOC100289178, or GNG12-AS1, covers a 370 kb
genomic region that starts near the GNG12 promoter,
runs through DIRAS3 in an antisense orientation, and ter-
minates within G-protein-coupled receptor 177 (GPR177,
also known as WLS [MIM 611514]) (Figure 1). DIRAS3 is
located within an intron of GNG12-AS1. The arrangement
of the two genes is similar to that found in imprinted retro-
gene pairs, where a gene is retrotransposed from the X
chromosome into a host gene. The retrotransposed gene
is imprinted and, in some cases, so is the host gene.13,14
Although DIRAS3 is not derived from the X chromosome
and is therefore not a retrogene, it is nonetheless possible
that GNG12-AS1might also be imprinted similarly to a ret-
rogene host.
Imprinted genes are associated with differentially meth-
ylated regions (DMRs), which comprise promoters and
insulator/ boundary elements.15 It has been shown that
CCCTC binding factor (CTCF) and cohesin play a role in
regulating imprinting by binding to the unmethylated
allele at insulator/boundary elements and a subset of pro-
moter DMRs.15 At several imprinted gene clusters, a pro-
moter DMR regulates the expression of an lncRNA that
silences adjacent genes in cis.16 LncRNAs (transcripts of1Cancer Research UK, Robinson Way, Cambridge CB2 0RE, UK; 2Institute of C
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and include ‘‘long intergenic noncoding RNAs’’ (lincRNAs)
and macro noncoding RNAs, which are inefficiently pro-
cessed and unspliced.17 The imprinted GNAS, KCNQ1,
and mouse Igf2r loci are examples of loci where allele-spe-
cific silencing of adjacent genes is mediated by lncRNAs.17
Imprinted lncRNAs such as Airn and KCNQ1OT1 silence
their target genes by recruiting chromatin modifiers: Airn
recruits H3K9me3 methyltransferase G9a to the mouse
Igf2r locus,18 and KCNQ1OT1 at the KCNQ1 locus binds
both G9a and polycomb repressive complex 2 (PRC2).19
It has been proposed that the regulation of gene expres-
sion in cis by lncRNA at Igf2r, Gnas, and Copg2 imprinted
gene clusters might be through the act of transcrip-
tional interference without the involvement of a mature
RNA.16 ‘‘Transcriptional interference’’ implies interference
between transcriptional machineries along adjacent
sequences.20,21 At the Igf2r locus, it has recently been
confirmed that imprinted silencing of Igf2r only requires
a transcriptional overlap of Airn at the Igf2r promoter to
interfere with recruitment of RNA polymerase.22
At nonimprinted loci, lncRNAs are increasingly being
shown to have a role in epigenetic gene regulation. Exam-
ples include HOTTIP and Mistral, which activate the
nearby genes at HOXA clusters by recruiting the trimethy-
lation of lysine 4 on histone H3 (H3K4me3) methyltrans-
ferase MLL1.23,24 LncRNAs might also regulate genes in
trans, as demonstrated by the HOTAIR transcript, which
is expressed from the HOXC cluster and recruits PRC2 to
silence the HOXD cluster on a separate chromosome.25
In this study, we characterize GNG12-AS1 and its
imprinting state at the DIRAS3 locus in normal and cancer
cell lines. We report that it is transcribed from a singlehild Health, University College London, 30 Guilford Street, London WC1N
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Figure 1. Organization of DIRAS3 and
the GNG12-AS1 Locus
(A) The organization of the entire GNG12-
AS1 locus (chr1: 68,297,971–68,668,670
[UCSC genome browser hg19) shows
CTCF binding sites (designated a–k), CpG
islands, and the positions of SNPs for
DIRAS3 and GNG12-AS1. The known
exons of GNG12-AS1 are enlarged for
clarity and marked 1–9.
(B) Enlarged view of DIRAS3 and its sur-
rounding region. Exon 2 of GNG12-AS1 is
11 kb downstream of DIRAS3, and exon 3
is 21 kb upstream. Differentially methyl-
ated DIRAS3-associated regions DMR1,
DMR2, and DMR3 are shown. DMR1
corresponds to the DIRAS3 promoter,
DMR2 corresponds to the transcription
start site (TSS), and DMR3 corresponds
to exon 2 of DIRAS3. Binding site CTCF-f
corresponds to DIRAS3 DMR1, and bind-
ing site CTCF-e corresponds to DIRAS3
DMR3.
(C) Schematic representation of imprinted
DIRAS3. DIRAS3-associated DMRs are
shown as lollipops (black represents
methylated, and white represents unme-
thylated). CTCF binds only to the
unmethylated DMR1. The arrow on the
paternal allele indicates expression and
direction of DIRAS3. Abbreviations are as
follows: M, maternal allele; and P, paternal
allele.promoter on both alleles and that specific isoforms are
spliced on one allele only. Cohesin plays a role in this
allele-specific splicing. We further show that transcription
of DIRAS3 and GNG12-AS1 is coordinately downregulated
in breast cancers. Where DIRAS3 is epigenetically silenced
in cancer cell lines, transcription of GNG12-AS1 is downre-
gulated allele specifically and becomes predominantly
monoallelic.Material and Methods
Human Tissue DNA and RNA Samples
Placenta DNA and RNA samples were obtained from G.E.M. at
the Institute of Child Health at University College London.
Samples were collected with informed consent under the
guidelines of the Hammersmith and Queen Charlotte’s and
Chelsea Hospitals Trust Research Ethics Committee (registration
no. 2001/6029). Total RNA from human tissues used in experi-
ments was commercially obtained from Ambion. DIRAS3 and
GNG12AS1 expression analyses utilized 79 breast tumor samples
and 36 normal breast samples obtained under ethical approval
from the Molecular Taxonomy of Breast Cancer International
Consortium.26The American Journal of Human GCell Lines and Reagents
Human mammary epithelial cells (HB2
cell line) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM,
GIBCO) supplemented with 10% fetalbovine serum (FBS), 10 ml/l penicillin-streptomycin solution
(P/S), 5 mg/ml insulin (Sigma), and 1 mg/ml hydrocortisone
(HC, Sigma). SUM159 cells were cultured in Ham’s F-12
medium (GIBCO) supplemented with 5% FBS, 5 mg/ml insulin,
and 1 mg/ml HC; MCF7, K562, and Hs27 cell lines were cul-
tured in DMEM with 10% FBS and 10 ml/l P/S. CAL51
cells were cultured in RPMI 1640 with 10% FBS, and MCF10A
cells were cultured in MEGM SingleQuots (Lonza). Cell lines
were cultured at 37C. For 5-azacytidine treatment, 5-aza-
20deoxycytidine (5-aza) (A3656, Sigma) was added to the
medium at 1 mM for 48 hr, as previously described.27 Alpha-
amanitin (Sigma) was used at 5 mg/ml for 24 hr. Antibodies,
siRNAs, and primers used in this study are in Table S1–S4 (avail-
able online).
RNA Interference
Cell lines were transfected with 50 nM of siRNAs targeting CTCF
(catalog no. M-020165-01), Rad21 (catalog no. M-006832-01),
and DIRAS3 (catalog no. M-008660-01) with the use of
DharmaFECT 3 and/or DharmaFECT 4 (Dharmacon) as per the
manufacturer’s instructions. Control siRNA was siGENOME Non-
Targeting siRNA Pool #2 (Dharmacon, catalog no. D-001206-14-
20). The cells were collected for RNA and protein analysis 48 hr
after transfection.enetics 93, 224–235, August 8, 2013 225
Nuclear Fractionation
For nuclear fractionation, HB2 cells were harvested and resus-
pended in 1 ml PBS, 1 ml buffer C1 (cell-lysis buffer, QIAGEN),
and 3 ml water and incubated for 15 min on ice. Then cells were
centrifuged at 2,500 rpm for 15 min, the supernatant was dis-
carded, and the nuclear pellet was kept for RNA extraction. Primers
used for GNG12-AS1 were against exon 7 (Table S3).RNA Isolation and Quantitative Real-Time PCR
RNA was extracted and reverse transcribed with the RNeasy Kit
and theQuantiTect Reverse Transcription Kit (QIAGEN). Quantita-
tive real-time PCRwas performed on a 7900HT Fast Real-Time PCR
System (Applied Biosystems) with Fast SYBR Green Master Mix
(Invitrogen). We used PCR Miner software28 to calculate both
the cycle threshold of each PCR and the amplification efficiency
of each primer pair. To determine the expression levels of
GNG12-AS1 transcripts, we used the assay for exons 7 and 8. To
determine the relative abundance of specific splice variants of
GNG12-AS1 transcripts, we used expression primers to exon-
exon junctions. Expression levels were normalized to GAPDH
expression (Table S3).Cell Lysis and Immunoblot
Cells were harvested and washed twice with PBS, resuspended in
lysis buffer (50 mM Tris-HCl, pH 8, 125 mM NaCl, 1% NP-40,
2 mM EDTA, 1 mM PMSF, and protease inhibitor cocktail [Roche])
and incubated on ice for 25 min. The proteins were denatured,
reduced, and separated by SDS-PAGE, and immunoblotting
was performed as described previously.29 Secondary antibodies
were conjugated with peroxidase, and immunobands were de-
tected with a Supersignal West Dura HRP Detection Kit (Thermo-
Scientific).Analysis of Allelic Expression
Cell lines, chromatin immunoprecipitation (ChIP) DNA, and
placenta samples were genotyped for exonic SNPs identified in
the UCSC Genome Browser (hg19). Informative (i.e., heterozy-
gous) samples were used in the analysis of allelic expression by
pyrosequencing (PSQ) and Sanger sequencing. For PSQ allelic
analysis of GNG12-AS1, long-range PCRs were performed with
primers located at exons 1 and 9. For analysis of splice variants
containing exon 2, long-range PCRs with primers located in exons
2 and 9 were performed. Each biological sample was assayed with
the same SNP for bothmajor and exon 2 isoforms. Terms ‘‘allele 1’’
and ‘‘allele 2’’ were used for unifying results between different cell
lines. For allelic expression of transcripts terminating at exon 7,
rs11209218 was utilized. Primers for PSQ assays are listed in Table
S5. For allele-specific enrichment of RNA polymerase II (RNAPII)
and CTCF binding, Sanger sequencing was carried out with the
quantitative real-time PCR products obtained after ChIP (primers
are listed in Table S4).Analysis of DNA Methylation
Analysis of DNA methylation was done by bisulfite conversion
with the EZ DNA Methylation-Gold Kit (Zymo Research) and sub-
sequent PSQ as previously described.30 PSQ assays for DIRAS3 re-
gions DMR1, DMR2, and DMR3 are listed in Table S6. Methylation
analysis by DNA immunoprecipitation was done as previously
described31 with an antibody (mAb-006) from Diagenode. Primers
are listed in Table S4.226 The American Journal of Human Genetics 93, 224–235, August 850 and 30 Rapid Amplification of cDNA Ends
50 and 30 rapid amplification of cDNA ends (RACE) was performed
with the RLM RACE Kit (Ambion). Primers for 30 and 50 RACE are
listed in Table S7.ChIP Assays
ChIP assays for RNAPII, CTCF, cohesin, and trimethylation of
lysine 36 on histone H3 (H3K36me3) were performed as described
previously32 with the use of antibodies as listed in Table S1. The
input and the immunoprecipitated materials were quantified by
QubitFluorometer (Life Technologies) with the dsDNA BR Assay
Kit (Invitrogen). Per ChIP experiment, 20–50 mg of chromatin
and 5 mg of antibody were used. The qPCR data were corrected for
DNA amount, and enrichment was normalized against the input
according to the formula 2[Ct(Ab)  log2(DF)]  [Ct(input)  log2(DF)].
The data were further normalized against the negative-control re-
gion FOXA1 for CTCF and RAD21 ChIP. RNAPII and H3K36me3
ChIP experiments were normalized against positive-control re-
gions GAPDH transcription start site (TSS) and GAPDH exon 6,
respectively. EachChIP experiment contained at least three biolog-
ical replicates, primers for which are listed in Table S4.Statistics
Unless otherwise indicated, an independent two-sample t test was
carried out for the statistical analysis in all experiments. Signifi-
cance of the paired siRNA experiments and paired 5-aza experi-
ments was calculated with a paired two-sample t test.
Values from all experiments were used for calculation of the
means and their respective SEMs. p values < 0.05 were considered
statistically significant. Correlation coefficients (R) (Figure S1)
were calculated with Pearson tests.Results
Confirmation of Genomic Imprinting of DIRAS3 in
Selected Normal and Breast Cancer Cell Lines
DIRAS3 is not present in the rodent lineage, so we selected
five human cell lines to study its effects on GNG12-AS1
expression (Table S8). First, we identified four human
cell lines with heterozygous SNPs in exon 2 of DIRAS3
(Table S8)—two normal cell lines (HB2 [breast epithelial]
and Hs27 [foreskin fibroblast]) and two breast cancer cell
lines (SUM159 and CAL51)—and examined allelic expres-
sion of DIRAS3. We confirmed that the normal cell lines
have imprinting of DIRAS3 transcription (monoallelic)
and that the cancer cell lines have loss of imprinting
(LOI), manifested as basal low levels of biallelic expression
(Figure S2A). The expression levels of DIRAS3 in normal
cell lines (Hs27, MCF10A, and HB2) were higher than
those in cancer cell lines (SUM159, CAL51, and MCF7)
(Figure 2A). DIRAS3 is normally expressed only from the
paternal allele. The maternal allele of DIRAS3 is silenced
and has a differentially methylated promoter (DMR2)
and an upstream CpG island containing a CTCF binding
site (DMR1).33 We therefore investigated the methylation
state of these DIRAS3 DMRs in our cell lines. None of the
cell lines had SNPs at the DMRs, so we used a PSQ assay to
determine the overall percentage of methylation at the, 2013
Figure 2. DIRAS3 and GNG12-AS1 Are
Coexpressed in Several Tissues and
Reduced in Breast Cancer
(A) DIRAS3 expression in a panel of tissues
and in cell lines. The dotted line marks the
background DIRAS3 expression in cell
lines with loss of imprinting.
(B) GNG12-AS1 expression in tissues and
cell lines. Expression levels were normal-
ized to GAPDH. Error bars represent the
SDs from at least three biological experi-
ments. Because of the wide expression
range, the y axis is split.
(C) Nuclear localization of GNG12-AS1 in
HB2 cells. U1 RNA is a control nuclear
RNA, and RPS18 is a control cytoplasmic
RNA. Values represent the median of three
replicate experiments5 SD.
(D) Coordinate reduction of DIRAS3 and
GNG12-AS1 in normal breast (n ¼ 72)
and tumor breast (n ¼ 36). ****p < 0.0001.DMRs. Two of the normal cell lines (HB2 and Hs27)
showed the expected 50% methylation at DMR1 and
DMR2, which is in accordance with normal imprinting
at the locus. The cancer cell lines (SUM159, MCF7, and
CAL51) were hypermethylated at DMR1. SUM159 and
CAL51 had 50% methylation at DMR2, and MCF7 had
hypermethylation at DMR2 (Figure S2B and Table S8).
The CpG island located within the DIRAS3 gene body
has been described as a DMR (DMR3).33 However, we
have previously found it to be hypermethylated in
normal tissues, suggesting that if it is a DMR, it is likely
to be tissue specific.15 Similarly, DMR3 was found to be
hypermethylated in all of our cell lines (Figure S2B). These
data confirm that the HB2 and Hs27 cell lines are suitable
models for normal DIRAS3 imprinting and that SUM159,The American Journal of Human GCAL51, and MCF7 are good models
for loss of DIRAS3 imprinting.
GNG12-AS1 Has Several Splice
Variants
Using RT-PCR with primers located in
exons 1 and 9, we confirmed that
GNG12-AS1 is expressed in a human
cDNA tissue panel and human cell
lines. RT-PCR products from human
kidney and the HB2 cell line were
cloned and sequenced. We found
that GNG12-AS1 has multiple splice
variants (Figure S3A). 50 and 30 RACE
with primers located in exons 7 and
9 (Figures S4A–S4E) showed a single
TSS that lies within exon 1 (and starts
at chr1: 68,298,000 [hg19]) and three
polyadenylation sites, as indicated in
Figure S3A. Exons 7 and 8 seemed to
be present in most of the transcripts.
Analysis of exon inclusion by mea-surement of the ratios of splice junctions relative to exons
7 and 8 indicated that transcripts with splice junctions
from exons 1 to 3 and from exons 1 to 2 are less frequent
(Figure S3B).
GNG12-AS1 Is Coexpressed with DIRAS3 in a Wide
Range of Tissues and Cell Lines
To determine whether GNG12-AS1 and DIRAS3 are coex-
pressed, we performed RT-PCR by using intron-spanning
primers in a panel of tissues and cell lines (Figures 2A
and 2B). DIRAS3 is highly expressed in the ovaries,
pancreas, testes, cervix, and breasts, whereas GNG12-AS1
has the highest expression in the pancreas, small intestine,
testes, liver, breasts, cervix, and adipose tissue. We
found that the expression of GNG12-AS1 is significantlyenetics 93, 224–235, August 8, 2013 227
Figure 3. GNG12-AS1 Is a RNAPII Tran-
script with an H3K36me3 Signature Char-
acteristic of a Transcribed Locus
(A) A schematic representation of the
GNG12-AS1 locus shows the relative loca-
tion of GNG12-AS1 exons (above the
line) and the locations of primers used
for ChIP analysis (bars below the line).
(B) RNAPII enrichment occurred
throughout the GNG12-AS1 locus in HB2
and SUM159 cells. Note the significant
reduction of RNAPII enrichment at
DIRAS3 for SUM159 cells. In the left panel,
representative chromatograms for SNP
analysis indicate biallelic enrichment in
HB2 cells and monoallelic enrichment in
SUM159 cells.
(C) Enrichment of H3K36me3 in HB2 and
SUM159 cells and representative chro-
matograms indicating allelic enrichment
for SNP analysis. Error bars represent the
SEM from three independent biological ex-
periments for HB2 cells and three indepen-
dent experiments for SUM159 cells.correlated with DIRAS3 expression in tissues (R ¼ 0.607,
Pearson correlation) and cell lines (R ¼ 0.960, Pearson cor-
relation) (Figures S1A and S1B).We also found a correlation
betweenGNG12-AS1 andGNG12 expression in tissues (R¼
0.553, Pearson correlation) and cell lines (R ¼ 0.912, Pear-
son correlation), which might be explained by the overlap
of their promoters (Figures S1C and S1D). GNG12-AS1
overlaps the 30 end of WLS. However, we observed no cor-
relation between GNG12-AS1 andWLS expression (Figures
S1E and S1F). We also investigated the cellular localization
of GNG12-AS1 and found that it is predominantly present
in the nucleus (Figure 2C).
DIRAS3 expression is known to be reduced in breast can-
cer; therefore, we examined expression levels of DIRAS3
and GNG12-AS1 in a panel of tumor cDNAs with matched
normal tissue from individuals with breast cancer. We
found that there was significantly less expression of both
DIRAS3 and the GNG12-AS1 in cancer tissues than in
normal breast tissues (p < 0.0001) (Figure 2D). Because228 The American Journal of Human Genetics 93, 224–235, August 8, 2013the 1p31 region, where DIRAS3 is
located, is often deleted in breast can-
cer, we checked our samples for loss of
heterozygosity (LOH). We did not
find LOH at this locus in our samples
(data not shown), suggesting that the
whole region is subject to epigenetic
silencing in breast cancer.
GNG12-AS1 Is an RNAPII
Transcript with H3K36me3
Signatures of Transcribed Gene
LncRNAsexhibit chromatin signatures
similar to those of transcribed coding
genes, such as enrichment of RNAPII,
H3K4me3, and H3K36me3.34,35To determine whether GNG12-AS1 is an RNAPII tran-
script, we treated HB2 cells with alpha-amanitin, which
is known to inhibit RNAPII at low concentrations (5 mg/
ml).36 After 24 hr, MYC, a positive RNAPII transcript con-
trol, was fully downregulated, whereas the RNAPI tran-
script, RPS18, was unaffected. GNG12-AS1 transcription
was also inhibited (Figure S5), suggesting that it is indeed
an RNAPII transcript.
We next compared RNAPII enrichment at GNG12-AS1
between normal cells with imprinted DIRAS3 (HB2) and
cancer cells with loss of imprinted DIRAS3 expression
(SUM159). The antibody used for ChIP recognizes both
serine 2 and serine 5 phosphorylated forms of RNAPII
and has a preference for serine 5. We found that RNAPII
was enriched at the TSSs of GNG12 and GNG12AS1, as
well as 1.6 and 2.2 kb downstream of the TSS in the first
intron of GNG12-AS1, confirming that it is transcribed by
RNAPII in both cell lines (Figures 3A and 3B). At the
DIRAS3 region, enrichment of RNAPII was only found in
Figure 4. GNG12-AS1 Transcripts Con-
taining Exon 2 Are Monoallelic
(A) GNG12-AS1 splice variants containing
exon 2 in HB2 cells. The majority of these
transcripts are expressed from allele A, as
determined by cloning of PCR products
and PSQ. These transcripts also contain
exon 3. Rare transcripts with exon 2 but
without exon 3 are produced only from
allele G.
(B and C) Allele-specific expression,
analyzed by PSQ, of GNG12-AS1major iso-
forms in cell lines and placenta (B) and
allele-specific expression, analyzed by
PSQ, of GNG12-AS1 isoforms containing
exon 2 in the same cell lines and placenta
(C). Error bars indicate themeans5 SDs of
three or more replicates. In (B) and (C),
two different SNPs were assessed, and the
results are therefore presented as alleles 1
and 2. The same SNPs were used in the
assay of transcripts 1–9 (major biallelic
transcripts) and transcripts 2–9 (monoal-
lelic transcripts containing exon 2).
(D) Maternal expression of GNG12-AS1
transcripts with exon 2 in two representa-
tive placenta triads (parents and placenta)
indicates expression from the maternal
allele.
(E) Proportion of transcript variants in
normal and cancer cell lines, as deter-
mined by qPCR. Relative abundance of
the transcripts was normalized to GAPDH
and related to expression of exons 7 and
8. n R 3 independent replicate experi-
ments.the normal HB2 cells and not in the SUM159 cancer cells,
which accords with the differences in DIRAS3 imprinting
and low levels of DIRAS3 expression in SUM159. Very
low RNAPII enrichment was seen at GNG12-AS1 exons 2
and 3, which fits with their low frequency of inclusion
into GNG12-AS1 transcripts. Allele-specific analyses using
a SNP located in exon 9 showed RNAPII occupation at
GNG12-AS1 on both alleles in the normal cell line HB2
(Figures 3A and 3B). However, in the cancer cell line
SUM159, we unexpectedly observed that occupation of
RNAPII was biased toward one allele, suggesting that
GNG12-AS1 might be expressed in a monoallelic manner
in SUM159 cells (Figure 3B).
H3K36me3 ChIP experiments in the same cell lines
confirmed that GNG12-AS1 is enriched with H3K36me3
within the gene body (Figure 3C). SNP analysis of precipi-
tated material indicated similar allele-specific binding forThe American Journal of Human GH3K36me3 as observed with RNAPII.
Thus, in HB2 cells, both GNG12-AS1
alleles have H3K36me3, whereas in
SUM159 cells, the enrichment is
skewed toward one allele. Together,
these data indicate that GNG12-AS1
has a chromatin signature similar
to that of other lncRNAs and pointtoward allelic differences in transcription between normal
and cancer cells (see below).
Some Splice Variants ofGNG12-AS1 Are Allele Specific
To determinewhetherGNG12-AS1 is imprinted, we utilized
SNPs located in exons 7 and 9 and examined the cloned se-
quences from the HB2 cell line. We found that most splice
variants are biallelic in this cell line. Additionally, splice var-
iants with alternative termination of transcription at exons
7 and 8d were found to be biallelic (data not shown). In
contrast, we found that splice variants containing exon 2
are predominantly monoallelic (allele A in HB2 cells) (Fig-
ure 4A). However, different allele specificities were found
depending on whether exon 3 was also included in the
isoforms containing exon 2. Exon 3 is absent in a small pro-
portion (10%) of isoforms containing exon 2, and these
transcripts originate from allele G in the HB2 cell line.enetics 93, 224–235, August 8, 2013 229
Figure 5. Demethylation of DMRs Restores Imprinted DIRAS3
Expression in Breast Cancer Cell Line SUM159 and Reduces
GNG12-AS1 Expression
(A) Methylation of DIRAS3 DMRs in control (nontreated) and
5-aza-treated SUM159 cells.
(B) Relative expression of DIRAS3, GNG12, WLS, and GNG12-AS1
in control and 5-aza-treated cells. Expression levels were normal-
ized to GAPDH. Because of the large expression differences, the
y axis is split.
(C) Allelic expression of DIRAS3 in SUM159 cells in control and
5-aza-treated cells.
(D) Allelic expression of GNG12-AS1 major isoforms in SUM159
cells upon 5-aza treatment.
(E) Allelic expression of GNG12-AS1 transcripts containing exon 2
in SUM159 cells. Error bars represent the SDs from at least four
independent biological replicates. The statistical significance
of the individual bars is compared to their respective control
bars; *p < 0.05, **p < 0.01, ***p < 0.001.We then developed assays to quantitatively detect allele
ratios for the major population of GNG12-AS1 isoforms
(captured with long PCR assays with primers in exons 1
and 9) (Figure 4B) and for isoforms containing exon 2
(captured with primers in exons 2 and 9 Figure 4C). Using
these assays, we were able to show that the normal breast
cell lines HB2 and MCF10a, as well as placenta tissue, are
biallelic for the major transcripts and monoallelic for the
exon 2 isoforms (Figures 4B and 4C). Genetic analyses in
three placenta trios indicated that themonoallelic isoforms
of GNG12-AS1 are expressed from the maternal allele,
whereDIRAS3 is silenced (Figure 4D).Maternal contamina-
tion in placenta samples was excluded by SNP analysis of
maternal markers (results not shown). Because there was
no evidence of methylation at the CpG island upstream
of theGNG12-AS1 promoter region in our cell lines (Figures
S6A–S6D), it seems likely that transcription initiates on
both alleles and that allele-specific splicing occurs at the
intron that contains the imprinted silenced DIRAS3.
GNG12-AS1 Is Predominantly Monoallelic in Breast
Cancer Cell Lines with Loss of DIRAS3 Imprinting
In the cancer cell lines (SUM159, Cal51, andMCF7), which
had loss of DIRAS3 imprinting (i.e., hypermethylation at230 The American Journal of Human Genetics 93, 224–235, August 8DMR1, Figure S2A and S2B), we expected to find that the
exon 2 isoforms are biallelic. Instead, we consistently
found that all the GNG12-AS1 transcripts are predomi-
nantly monoallelic and on the same allele as the exon 2
isoforms (change in biallelic 50% to 50% ratio to at least
70% to 30% ratio in cancer cell lines [Figures 4B and
4C]). Given that we found these exon 2 isoforms to be of
maternal origin in the placenta, we extrapolate that in can-
cer cell lines the monoallelic expression is biased toward
the maternal allele upon silencing of the paternally ex-
pressed DIRAS3 allele. The monoallelic expression in the
cancer cell lines is consistent with the allele-specific
enrichment observed with RNAPII and H3K36me3 ChIP
experiments (Figure 3). To exclude the possibility that
the observed allele bias for GNG12-AS1 was due to an in-
crease in exon 2 isoforms, we analyzed the proportions
of the variant isoforms in normal (HB2) and cancer
(SUM159) cell lines. We found no increase in the exon 2
isoforms in the SUM159 cell line, confirming that splicing
choice is not responsible for monoallelic expression of
GNG12-AS1 in cancer cell lines (Figure 4E). These results
indicate that neoplastic silencing of the normally active
DIRAS3 allele also reduces transcription of the GNG12-
AS1 lncRNA in cis but does not affect its transcription on
the homologous chromosome with the constitutively
silent imprinted DIRAS3 allele. This interpretation could
explain the apparent gain of imprinting of GNG12-AS1
in cancer cell lines.
Demethylation of a Cancer Cell Line with Loss of
DIRAS3 Imprinting Leads to Upregulation of DIRAS3
Expression and a Decrease in the Levels ofGNG12-AS1
Transcripts
In the breast cancer cell lines, despite predominantly
monoallelic GNG12-AS1 expression, the GNG12-AS1 pro-
moter was unmethylated (Figure S6). To examine whether
we could change allele-specific transcription of GNG12-
AS1 by reducing DNA methylation at the DIRAS3 DMRs,
we treated the SUM159 cell line with 5-aza. SUM159 was
hypermethylated at all DMRs, and after 5-aza treatment,
the methylation at DMR1, DMR2, and DMR3 was
decreased to 50%, 40%, and 40%, respectively (Figure 5A).
DIRAS3 expression was increased by 10-fold predomi-
nantly on one allele, so it appeared to be similar to
imprinted expression in normal cells (Figures 5B and 5C).
The skewed upregulation of DIRAS3 expression after
5-aza treatment suggests that the constitutively silent
imprinted allele is resistant to 5-aza treatment.
Demethylation of the DIRAS3 locus and concomitant
upregulation ofDIRAS3 expression resulted in a significant
reduction of GNG12-AS1 expression. However, there was
no effect on GNG12 or WLS (Figure 5B), suggesting that
increased transcription of DIRAS3 might attenuate tran-
scription of the lncRNA. Indeed, GNG12-AS1 allelic expres-
sion changed from predominantly monoallelic (70% to
30% ratio of C to T) to completely monoallelic (reaching
a 94% to 6% ratio of C to T), indicating that the reduction, 2013
of transcription occurs at the allele that already has
reduced transcription in the cancer cell line. Because
GNG12-AS1 repression occurs on the same chromosome
as the increased DIRAS3 expression, this could suggest
transcriptional interference from the upregulated DIRAS3
allele (Figures 5D and 5E).
Treating the normal HB2 cell line with 5-aza further
shows that expression levels of GNG12-AS1 and DIRAS3
are interrelated. In this cell line, 5-aza had a smaller effect
on DNA methylation levels, confirming that the con-
stitutively silent DIRAS3 is resistant to 5-aza treatment
(Figure S7A). The treatment with 5-aza had an inhibitory
effect on DIRAS3 expression, presumably as a result of a
slight decrease inmethylation at the somatic DMR3within
the gene body (Figure S7A and S7B). As expected, DIRAS3
expression remained monoallelic (Figure S7C). Interest-
ingly, reduced expression of DIRAS3 was accompanied
by a slight increase in expression of GNG12-AS1. How-
ever, GNG12-AS1 expression remained biallelic, and tran-
scripts with exon 2 remained monoallelic (Figures S7D
and S7E).
DIRAS3 has been shown to physically interact with
STAT3, and changes in DIRAS3 expression might therefore
affect transcription of STAT3 target genes.37 In order to
examine whether the above observed changes in GNG12-
AS1 transcription are directly in response to increased
DIRAS3 transcription or indirectly due to DIRAS3 signaling
pathways, we used siRNA to depleteDIRAS3 in normal cells
(HB2 and HS27) and examined the effect on expression of
GNG12-AS1. We found no change in GNG12-AS1 expres-
sion after depletion of DIRAS3 (Figure S8). Because
siRNA-mediated silencing targets genes posttranscription-
ally, these results indicate that the GNG12-AS1 transcript
is not regulated by DIRAS3. The results further support a
hypothesis that the act of increased DIRAS3 transcription
in cells treated with 5-aza affects GNG12-AS1 expression.
CTCF and Cohesin Binding at the DIRAS3 DMRs Is
Required for DIRAS3 Expression, but Not for that of
GNG12-AS1
The UCSC Genome Browser includes several annotated
CTCF binding sites within the transcription unit of
GNG12-AS1 (Figure 1A). At DIRAS3, both DMR1 and
DMR3 have CTCF binding sites (CTCF-f and CTCF-e,
respectively, in Figure 1A). We confirmed that at DMR1,
CTCF binds to the unmethylated allele in two normal
cell lines (Figure S9A). We examined whether any of the
CTCF sites are within CpG islands and found that, in addi-
tion to DMR1 and DMR3, CTCF-k is also a CpG island
(within GNG12-AS1 in intron i8b/9). This region has fully
methylated DNA in HB2 and SUM159 cells (data not
shown), indicating that it is not an allele-specific DMR.
CTCF ChIP analysis and sequencing of informative SNPs
at CTCF sites b, c, g, and i indicate that these CTCF sites
are bound on both alleles in the HB2 cell line (Figures
S9B and S9C). Thus, DMR1 is the only region likely to
have allele-specific CTCF binding within the locus.The AmerWe then analyzed CTCF-cohesin binding profiles at
GNG12-AS1 in HB2 and SUM159 cells. We used the
CTCF-b site as a positive reference for normalization and
found that CTCF and the cohesin subunit RAD21 bind
strongly to the CTCF-b, CTCF-c, and CTCF-i sites in both
cell lines (Figures S10A and S10B). The CTCF-k site was
less strongly enriched with CTCF in these cells and had
no enrichment of RAD21 in the SUM159 cells. This weaker
CTCF enrichment might have been due to DNA methyl-
ation, as mentioned above. At sites DMR1 (CTCF-f) and
CTCF-g, CTCF and RAD21 were bound in the normal
HB2 cell line and not in the cancer cell line (Figure S10).
Although it was expected that in the cancer cell line hyper-
methylation and loss of DIRAS3 imprinting would exclude
CTCF binding at the DMRs, the additional lack of CTCF
binding to the CTCF-g site was unexpected. CTCF-g is
located 7 kb upstream of DMR1, and the differential bind-
ing between the cell lines at this site suggests that it might
either be tissue specific or absent in cancer cell lines.
Inspection of CTCF binding profiles for several cell lines
on the UCSC Genome Browser indicated that CTCF-g is
generally a strong binding site for CTCF. Some cancer cell
lines, such as MCF7, HeLaS3, or CACO2 (in which CTCF
binding to both DMR1 and DMR3 is low), similarly exhibit
no CTCF binding at CTCF-g. Other cell lines (e.g., HCT16,
WERI-Rb-1, and human embryonic kidney 293) that have
CTCF binding at DMR3 also have CTCF peaks at CTCF-g
(Figure S11). These data indicate that CTCF binding within
DIRAS3 and the CTCF-g site might be functionally linked.
The presence of CTCF at DIRAS3 DMR1 might positively
regulate DIRAS3 expression, as evidenced by the recruit-
ment of CTCF to DMR1 upon 5-aza-mediated demethyla-
tion in SUM159 cells (Figure S12).
To determine the effect of CTCF binding on expression
of DIRAS3 and GNG12-AS1, we knocked down CTCF and
cohesin with siRNAs in three different cell lines (HB2,
HS27, and SUM159), as shown in Figure 6A (left panel).
In all three cell lines, DIRAS3 expression was reduced (by
65% in HB2, by 73% in Hs27, and by 40% in SUM159
[Figure 6B]). The decrease in DIRAS3 expression in
SUM159 cells (albeit less than in normal cell lines) was un-
expected, given that the CTCF binding site at DMR1 is
hypermethylated. It’s likely that the low basal levels of
DIRAS3 in SUM159 cells are associated with the small pro-
portion of unmethylated DMR1 sites. In the normal cell
lines, the decrease in DIRAS3 expression after CTCF or
cohesin knockdown indicates that CTCF and cohesin
binding at DMR1 positively regulates DIRAS3 expression
on the paternal allele. Despite the reduction of DIRAS3
expression after CTCF knockdown, GNG12-AS1 transcript
levels and allelic expression were unchanged (Figure 6C
and 6D). GNG12-AS1 levels appeared to not be affected
by CTCF knockdown, which is surprising because the
lncRNA is transcribed through several CTCF sites.
Although CTCF has previously been reported to play a
role in cotranscriptional splicing,38 we did not consistently
find an increase in exon 2 isoforms upon CTCF depletion.ican Journal of Human Genetics 93, 224–235, August 8, 2013 231
Figure 6. CTCF and Cohesin Binding at
the DIRAS3 DMRs Regulates DIRAS3
Expression
Cohesin is required for exon 2 skipping
near the active DIRAS3 allele.
(A) Immunoblots showing the efficiency
of CTCF and RAD21 knockdown by siRNA
in HB2, HS27, and SUM159 cell lines.
(B) DIRAS3 expression levels decreased
upon CTCF and cohesin (Rad21) knock-
down in all cell lines.
(C) Overall GNG12-AS1 expression levels
did not change upon CTCF and cohesin
(Rad21) knockdown.
(D) Allelic expression of the GNG12-AS1
major isoforms did not change after
siRNA-mediated CTCF and cohesin deple-
tion in HB2 cells.
(E) Expression of GNG12-AS1 isoforms
with exon 2 increased in normal cell lines
upon cohesin depletion, but not with
CTCF depletion. Cancer cells were unaf-
fected.
(F) Allelic expression ofGNG12-AS1 exon 2
isoforms in CTCF and cohesin-siRNA-
treated HB2 cells. A significant change in
allele ratio was found after cohesin deple-
tion. At least three technical replicates
were performed for each biological ex-
periment. Error bars represent the SDs
from at least three independent biological
experiments. The statistical significance of
the individual bars is compared to their
respective control bars; *p < 0.05, **p <
0.01, ***p < 0.001.However, we found that cohesin knockdown resulted in a
2-fold increase of GNG12-AS1 exon 2 isoforms (Figure 6E)
in the normal cell lines, HB2 and Hs27, but not in cancer
cell line SUM159. SNP analysis in the HB2 cell line revealed
a shift in allele ratios toward biallelic expression of the
exon 2 isoform (Figure 6F). These results might suggest
that cohesin-mediated stabilized looping at the locus has
a role in determining whether an exon is included during
cotranscriptional splicing. We do not have an immediate
explanation for the changes in allele-specific splicing
with cohesin depletion and not with CTCF. It might be
that despite a strong reduction of CTCF protein levels,
CTCF binding to DNA was only marginally reduced by
RNAi, as previously observed.39
From the above data and under the assumption that
exon 2 isoforms of GNG12-AS1 are from the maternal
allele, where DIRAS3 is silenced through imprinting, we232 The American Journal of Human Genetics 93, 224–235, August 8, 2013propose that the inclusion of exon 2
requires (1) that transcription of
GNG12-AS1 be above a threshold level
and (2) that cohesinmust be absent at
DMR1 and DMR3. SUM159 cells lack
cohesin at DMR1 and DMR3 on both
alleles but express GNG12-AS1 on
one allele only and hence include
exon 2 in a monoallelic fashion.Normal cells have biallelic expression of GNG12-AS1 but
have no cohesin binding at the DMRs on one allele, which
enables the inclusion of exon 2 during splicing.Discussion
Figure 7 summarizes our findings and demonstrates the
relationship between the imprinted DIRAS3 and the
lncRNA GNG12-AS1. In our studies, GNG12-AS1 was not
imprinted in non-cancer cells. However, one caveat is
that we only studied cell lines and placenta tissues, and
therefore our results do not preclude GNG12-AS1’s being
imprinted in a tissue-specific manner. In cancer cell lines,
monoallelic GNG12-AS1 transcription is associated with
loss of DIRAS3 imprinting. This intriguing observation re-
quires genetic and expression analyses in primary tumor
Figure 7. GNG12-AS1 Expression and Splicing Model in Normal
and Cancer Cells
(A) In normal cells,GNG12-AS1was expressed from bothmaternal
(‘‘M’’) and paternal (‘‘P’’) alleles, and inclusion of exon 2 occurred
on the maternal allele.
(B) In cancer cell lines, GNG12-AS1 expression was inhibited on
the paternal allele, and the lncRNA was predominantly expressed
from thematernal allele. The expression of transcripts with exon 2
remained monoallelic from the maternal allele.tissues for determining whether neoplastic silencing of
DIRAS3 is accompanied by monoallelic expression of
GNG12-AS1 in vivo.
Our preliminary screen in breast cancer tissues strongly
indicated that expression of GNG12-AS1 and DIRAS3 is
coordinately reduced in breast cancer. We have excluded
loss of heterozygosity at this locus in our samples, so the
silencing is likely to occur via an epigenetic mechanism
that potentially spreads across the locus. This acquired
silencing mechanism during neoplasia is unlikely to be
the same as the innate imprinted silencing that occurs in
the maternal germline. Indeed, the constitutively silenced
maternal DIRAS3 allele was found to be more resistant to
5-aza-mediated DNA demethylation in the cell lines stud-
ied here, suggesting that differential epigenetic silencing
marks are present on the imprinted and the neoplastic
silenced alleles. Moreover, it seems that a gain of DNA
methylation alone is not sufficient to silence GNG12-AS1
in cis, given that 5-aza treatment upregulated DIRAS3
expression levels without restoring biallelic GNG12-AS1
expression. Interestingly, theDIRAS3 region has been iden-
tified as a contiguous region of genes suppressed by long-
range epigenetic silencing in prostate cancer.40
RNA processing is increasingly being shown to occur co-
transcriptionally, and chromatin structure has been shown
to play a role in alternative splicing.41–43 Parent-of-origin-The Amerspecific transcriptional termination has been described at
the imprinted retrogene H13-Mcts244 and Herc3-Nap1l545
loci. The GNG12-AS1 locus is an unusual and intriguing
example of parent-of-origin-specific splicing.
Splicing has been linked to RNAPII pausing at CTCF
binding sites.38 However, exon 2 of GNG12-AS1, where
transcription is likely to pause, does not have a CTCF bind-
ing site. Thus, if CTCF has a role in alternative splicing of
GNG12-AS1, it would have to act from a more distant
CTCF site, such as at DMR1 or another site. Knockdown
of cohesin resulted in a decrease in DIRAS3 expression
and additionally in biallelic splicing of exon 2 on both
alleles, indicating that cohesin has a role in exon 2 skip-
ping. CTCF and cohesin occur at the same sites at this
locus, and because CTCF binding is required for the recruit-
ment of cohesin,46 it is surprising that depletion of CTCF
does not have the same effect on exon 2 splicing as cohesin
does. Cohesin and CTCF have recently been shown to
have distinct roles despite their co-occupancy.47 One
explanation of our observation of the cohesin effect on
splicing might be that it is more difficult to effectively re-
move CTCF from chromatin and that although reduced
CTCF binding is sufficient to inhibit transcription of
DIRAS3, there is still enough cohesin recruited to enable
exon 2 skipping. Serendipitously, the reduction in DIRAS3
transcription with CTCF knockdown not only excludes a
direct role for CTCF in exon 2 splicing but also potentially
excludes effects of DIRAS3 transcription.
Determining the function of GNG12-AS1 will require
further studies. Because it is a nuclear transcript, it might
have both trans and cis functions in gene regulation. In
addition, its variety of isoforms could potentially provide
additional diversity in its regulatory repertoire. This locus
is also a goodmodel system for future studies of long-range
effects of CTCF-cohesin binding on splicing and allele
exclusion. In this work, we have shown that an imprinted
gene can influence the splicing of a nonimprinted gene.
GNG12-AS1, which includes DIRAS3, is a model locus for
the study of a novel role for cohesin in the regulation of
alternative splicing.Supplemental Data
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